SaschaNiluGoonewardenaMD
Cardiology • Ann Arbor, MIAdult Congenital Heart Disease
Assistant Professor of Medicine
Dr. Goonewardena is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
24 Frank Lloyd Wright Dr
Ann Arbor, MI 48105Phone+1 734-998-7400Fax+1 734-647-0387
Education & Training
University of MichiganFellowship, Cardiovascular Disease, 2007 - 2011
University of ChicagoResidency, Internal Medicine, 2003 - 2006
University of Michigan Medical SchoolClass of 2003
Certifications & Licensure
MI State Medical License 2007 - 2026
IL State Medical License 2003 - 2008- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- How to differentiate obstructive from non-obstructive CAD with PET: Developments in high-resolution regional quantification of MBF and MFR.Jennifer M Renaud, Mouaz H Al-Mallah, Prem Soman, Robert A deKemp, Rob S B Beanlands
Journal of Nuclear Cardiology. 2024-11-01 - The complete blood count and cardiovascular disease: analyses across six cohorts of 23,370 adults.Sascha N Goonewardena, Venkatesh L Murthy
Medrxiv. 2024-10-18 - Response by Goonewardena et al to Letter Regarding Article, "Monocyte-Mediated Thrombosis Linked to Circulating Tissue Factor and Immune Paralysis in COVID-19".Sascha N Goonewardena, Qinzhong Chen, Ashley M Tate, Olga G Grushko, Dilna Damodaran Puthiya Veettil
Arteriosclerosis, Thrombosis, and Vascular Biology. 2024-09-01
Press Mentions
First-in-Human Trial for Oral Drug to Remove Radioactive ContaminantsMay 15th, 2023- First-in-Human Trial of Oral Drug to Remove Radioactive Contamination BeginsMay 15th, 2023
- PCSK9 Inhibitors for Severe COVID? Pilot Trial Signals of BenefitJanuary 24th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
